GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Checkpoint Therapeutics
Checkpoint Therapeutics is a biotech company developing cancer treatments. Its stock price is volatile and dependent on clinical trial results. This chart reflects investor confidence in the potential of its oncology drugs.
Share prices of companies in the market segment - Cancer cure
Checkpoint Therapeutics is a biopharmaceutical company focused on the development and commercialization of cancer immunotherapy drugs. We categorize it as a Cancer Treatment company. The chart below shows how investors value companies in this highly competitive sector.
Broad Market Index - GURU.Markets
Checkpoint Therapeutics is an oncology company developing immunotherapeutic drugs for cancer treatment. Its scientific advancements make it a prominent player in the GURU.Markets index. The chart below represents the entire market. Find out how Checkpoint shares compare to the overall market.
Change in the price of a company, segment, and market as a whole per day
CKPT - Daily change in the company's share price Checkpoint Therapeutics
For Checkpoint Therapeutics, an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Cancer cure
Checkpoint Therapeutics is a biopharmaceutical company developing immuno-oncology drugs for the treatment of cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating CKPT stock.
Daily change in the price of a broad market stock, index - GURU.Markets
Checkpoint Therapeutics is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Checkpoint Therapeutics
Checkpoint Therapeutics' year-to-date performance is a story about its oncology drug development. Its market cap over the next 12 months depends entirely on the FDA's decision on its PD-L1-targeted antibody. Approval for the skin cancer treatment would be a fundamental breakthrough for the company, transforming it into a commercial enterprise.
Annual dynamics of market capitalization of the market segment - Cancer cure
Checkpoint, a late-stage biotech company developing cancer treatments, is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Checkpoint Therapeutics is an immuno-oncology company whose stock is a bet on a new generation of cancer drugs. Its performance is completely disconnected from the market and is determined by news of the clinical successes or failures of its drugs. It's a high-risk play, where scientific data can change everything overnight.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Checkpoint Therapeutics
Checkpoint is a late-stage oncology company. Its monthly performance is extremely sensitive to regulatory decisions. FDA news regarding its lead drug can cause multiple price changes in a short period of time.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Checkpoint Therapeutics is a biotech company developing a portfolio of oncology drugs, including checkpoint inhibitors. The chart below shows how investors assessed the prospects of companies betting on proven mechanisms in immuno-oncology, albeit in a highly competitive environment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Checkpoint Therapeutics is a clinical-stage oncology company. Its shares are a classic biotech venture capital investment. Their value is determined not by general market trends, but by progress in clinical trials. This is a high-risk bet on the success of a specific scientific approach.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Checkpoint Therapeutics
Checkpoint Therapeutics is a late-stage oncology company seeking to commercialize its skin cancer treatment. Its weekly stock price is heavily dependent on news about its application's review process with regulators like the FDA.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Checkpoint Therapeutics develops new oncology drugs. As a biotech startup, its value depends almost entirely on the prospects of clinical trials. The chart below shows whether Checkpoint's share price reflects unique company news or general sentiment in the high-risk oncology sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Checkpoint is a clinical-stage oncology company. Its shares are buoyed by anticipation of trial results. The chart clearly demonstrates how its performance is driven by scientific news rather than general market trends, creating its own unique path.
Market capitalization of the company, segment and market as a whole
CKPT - Market capitalization of the company Checkpoint Therapeutics
Checkpoint Therapeutics' market capitalization chart is that of a late-stage biotech focused on oncology drug development. Its low valuation reflects the risks associated with regulatory approval and competition. It's a high-risk bet that its drug candidates will successfully reach market.
CKPT - Share of the company's market capitalization Checkpoint Therapeutics within the market segment - Cancer cure
Checkpoint Therapeutics is a biotech company focused on oncology. Its market capitalization in the vast pharmaceutical sector is minimal, which is typical for a clinical-stage developer. This metric reflects the market's confidence in the success of its experimental cancer drugs compared to hundreds of other startups.
Market capitalization of the market segment - Cancer cure
The chart below shows the biotech sector's market capitalization. Checkpoint Therapeutics is a company focused on developing and commercializing oncology drugs, often licensed from other companies. Its market strategy isn't about revolutionary discoveries, but rather about effective clinical trials and finding a fast path to market.
Market capitalization of all companies included in a broad market index - GURU.Markets
Checkpoint Therapeutics is an oncology company developing immunotherapy drugs. Its market capitalization is based on the approval of its candidates. The chart below shows the economic weight of late-stage biotech companies developing cancer drugs.
Book value capitalization of the company, segment and market as a whole
CKPT - Book value capitalization of the company Checkpoint Therapeutics
Checkpoint Therapeutics' book value is its intellectual property in its late-stage oncology pipeline. The chart tells the story of a biotech company focused on bringing its candidates to regulatory approval, where all its capital is invested in creating an intangible asset.
CKPT - Share of the company's book capitalization Checkpoint Therapeutics within the market segment - Cancer cure
Checkpoint Therapeutics develops oncology drugs. The chart shows its share of actual R&D assets. These include its clinical programs and partner laboratories, which provide the resources for developing and testing new cancer treatments.
Market segment balance sheet capitalization - Cancer cure
Checkpoint Therapeutics is a biopharmaceutical company focused on developing oncology drugs. Their asset-light model emphasizes clinical trials rather than plant construction. A book-to-market chart shows their modest financial base, as their primary asset is science.
Book value of all companies included in the broad market index - GURU.Markets
Checkpoint Therapeutics' balance sheet includes laboratories and investments in clinical research to develop new cancer treatments. The chart shows how the company is building its scientific and material capital to advance its candidates.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Checkpoint Therapeutics
Checkpoint Therapeutics develops oncology drugs. Its book value is minimal, consisting of cash and lab equipment. The chart is a pure barometer of confidence in the success of clinical trials. Each peak and trough on it represents not a change in assets, but rather the market's reaction to news of a potential cancer cure.
Market to book capitalization ratio in a market segment - Cancer cure
Checkpoint Therapeutics is a biotech company developing a portfolio of oncology drugs. Its valuation is based on the combined potential of its clinical programs, not current revenue. The chart shows how its market capitalization, driven by drug approval hopes, relates to its current assets.
Market to book capitalization ratio for the market as a whole
Checkpoint Therapeutics develops cancer treatments. Like many biotech companies, its market value is based almost entirely on clinical trial expectations. This metric demonstrates the vast gap between investor estimates of the drug's future potential and the company's modest current book value.
Debts of the company, segment and market as a whole
CKPT - Company debts Checkpoint Therapeutics
Checkpoint Therapeutics is a biotech company developing a portfolio of oncology drugs. This chart illustrates its financial strategy. The company aims to advance its candidates through clinical trials, which requires significant capital, which it raises through equity issuances and partnerships.
Market segment debts - Cancer cure
Checkpoint Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology treatments. Funding long-term, costly clinical trials is its primary objective. This chart reflects the high financial risk inherent in companies seeking to develop new cancer treatments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Checkpoint Therapeutics
Checkpoint Therapeutics is a clinical-stage oncology company. This chart shows its financial structure. For a biotech company whose future depends on clinical trial results and regulatory approval, debt is an unaffordable luxury. Financing must be equity-based to avoid the risk of bankruptcy in the event of failure.
Market segment debt to market segment book capitalization - Cancer cure
Checkpoint Therapeutics is a biopharmaceutical company focused on developing immuno-oncology drugs. This chart shows the debt burden in the biotech sector. It is a key indicator of the company's ability to fund its clinical research and development in this highly competitive field.
Debt to book value of all companies in the market
Checkpoint Therapeutics is a clinical-stage oncology company. Its future depends on the success of clinical trials and access to financing. This chart of total market debt serves as a barometer of the investment climate, showing how easy or difficult it is for companies like Checkpoint to raise funds to continue their expensive development.
P/E of the company, segment and market as a whole
P/E - Checkpoint Therapeutics
Checkpoint Therapeutics is a biotechnology company specializing in the development and commercialization of innovative immuno-oncology therapies. This graph reflects the high risks associated with clinical development. Its dynamics depend entirely on the results of trials and FDA approval decisions for its candidates.
P/E of the market segment - Cancer cure
Checkpoint Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology therapeutics for the treatment of cancer. This chart shows the average valuation for the oncology sector, reflecting how investors assess the risks and potential of smaller biotech companies.
P/E of the market as a whole
Checkpoint Therapeutics is a biotech company developing drugs to treat cancer. Like other companies at this stage, its valuation is a pure bet on the success of its scientific developments. It has no connection to the general economic cycles depicted by this chart. Checkpoint's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Checkpoint Therapeutics
Checkpoint Therapeutics is a biopharmaceutical company developing immuno-oncology drugs for the treatment of cancer. This chart shows market expectations for the success of its clinical programs. Future revenue depends on regulatory approvals and the commercial potential of its drug candidates in a competitive environment.
%20P%2FE%20Checkpoint%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Checkpoint-Therapeutics&v=1772513477576 "Chart of the company's future (projected) P/E Checkpoint Therapeutics")
Future (projected) P/E of the market segment - Cancer cure
Checkpoint Therapeutics is a biopharmaceutical company developing immuno-oncology and targeted therapies for cancer treatment. The chart reflects average expectations for the oncology segment. Checkpoint Therapeutics' position relative to this benchmark reflects investor assessment of its strategy for licensing and developing promising drug candidates for market launch.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772513477607 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Checkpoint Therapeutics is a clinical-stage biopharmaceutical company focused on acquiring, developing, and commercializing novel cancer treatments. The company is developing a portfolio of targeted therapies and immuno-oncology. This chart of overall market expectations illustrates investor risk appetite associated with funding oncology developments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513477630 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Checkpoint Therapeutics
Checkpoint Therapeutics is a biotechnology company focused on the development and commercialization of novel cancer treatments, particularly immuno-oncology therapies. Its financial performance reflects significant investments in clinical trials. Future profitability depends on the approval and successful launch of its drug candidates.
Profit of companies in the market segment - Cancer cure
Checkpoint Therapeutics is a biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology therapeutics for the treatment of cancer. This chart reflects the overall revenue of the cancer treatment sector. It demonstrates the overall success of the industry in commercializing new therapeutic approaches and the overall level of investment in this vital area.
Overall market profit
Checkpoint Therapeutics is a biopharmaceutical company developing cancer treatments. Its success depends entirely on clinical trial results and regulatory approval. The overall economic situation, reflected in this chart, does not affect the demand for cancer drugs but is important for attracting the investment needed to complete development.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Checkpoint Therapeutics
Checkpoint Therapeutics is a biotechnology company focused on the development and commercialization of immuno-oncology therapies. Future revenue is contingent on regulatory approval. This chart reflects analyst expectations for the commercial potential of its candidates for the treatment of various cancer types, which are associated with high clinical risks.
%20profit%20of%20the%20company%20Checkpoint%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Checkpoint-Therapeutics&v=1772513477774 "Graph of future (projected) profit of the company Checkpoint Therapeutics")
Future (predicted) profit of companies in the market segment - Cancer cure
Checkpoint Therapeutics is a biotech company focused on developing and commercializing innovative cancer treatments, including immunotherapy. Its future depends on successful clinical trials and regulatory approval. This chart shows profitability projections for the entire biotech sector, providing context for assessing Checkpoint's potential and risks.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772513477784 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Checkpoint Therapeutics is a biotech company focused on developing oncology drugs. Its current value is determined not by revenue, but by the potential of its research and development and the results of clinical trials. Therefore, its performance is weakly correlated with overall economic trends, as illustrated by this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513477798 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Checkpoint Therapeutics
Checkpoint Therapeutics is a biotech company focused on developing oncology drugs. Being in the clinical stage, it has almost no revenue. Its market value, reflected here, is a valuation of its pipeline of potential drugs. The indicator's dynamics reflect news about the progress of clinical trials.
P/S market segment - Cancer cure
Checkpoint Therapeutics is a biopharmaceutical company developing a portfolio of oncology drugs targeting various types of cancer. Future revenue depends on the approval and commercialization of these drugs. This oncology sector chart helps assess how investors view Checkpoint's broad pipeline and strategy.
P/S of the market as a whole
Checkpoint Therapeutics is a biotechnology company focused on the development and commercialization of novel immuno-oncology drugs for the treatment of cancer. Its pipeline includes several candidates in various stages of clinical trials. This market revenue valuation chart helps understand how investors view the company's potential in one of the most competitive areas of pharmaceuticals.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Checkpoint Therapeutics
Checkpoint Therapeutics is a biotechnology company focused on the development and commercialization of innovative immuno-oncology therapeutics for the treatment of cancer. This chart shows how the market assesses the future commercial potential of its drug candidates. It reflects investor expectations for clinical trial success and regulatory approval.
%20P%2FS%20Checkpoint%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Checkpoint-Therapeutics&v=1772513477850 "The graph of the company's future (projected) P/S Checkpoint Therapeutics")
Future (projected) P/S of the market segment - Cancer cure
Checkpoint Therapeutics is a biotechnology company developing a portfolio of oncology drugs, including checkpoint inhibitors, in combination with other therapies. The company's valuation is based on investors' belief in the potential of its clinical programs for treating various cancer types, which entails high risks and a lengthy development process.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772513477865 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Checkpoint Therapeutics is a biopharmaceutical company developing drugs to treat oncology. Its success depends on the results of clinical trials. In the overall revenue growth picture illustrated by the chart, Checkpoint represents an innovative sector with a targeted approach.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513477879 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Checkpoint Therapeutics
Checkpoint Therapeutics is a clinical-stage oncology company. It is developing cancer treatments but does not yet have commercial products. Consequently, the company has no sales revenue, and any revenue reflected in the chart is likely related to licensing agreements or other forms of funding.
Sales of companies in the market segment - Cancer cure
Checkpoint Therapeutics (CKPT) is a biopharmaceutical company focused on the development and commercialization of innovative cancer treatments, particularly checkpoint inhibitors. This chart shows revenue in the oncology sector. Checkpoint aims to commercialize new immunotherapies that could become an important part of the cancer arsenal.
Overall market sales
Checkpoint Therapeutics is a biotech company developing cancer treatments. Its growth depends on successful clinical trials and raising funding. This graph, reflecting the overall market situation, affects the availability of capital for the biotech sector. During periods of growth, investors are more willing to invest in companies with promising oncology developments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Checkpoint Therapeutics
Checkpoint Therapeutics is a biotechnology company focused on developing and commercializing innovative cancer treatments. Its future revenue depends on the success of clinical trials and regulatory approvals. This chart reflects analyst forecasts, which essentially represent an estimate of the likelihood of commercialization of its oncology drug candidates.
%20sales%20of%20the%20company%20Checkpoint%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Checkpoint-Therapeutics&v=1772513477935 "Schedule of future (projected) sales of the company Checkpoint Therapeutics")
Future (projected) sales of companies in the market segment - Cancer cure
Checkpoint Therapeutics is a biopharmaceutical company focused on the development and commercialization of targeted oncology therapies. The forecast on this chart reflects the potential future revenue from their pipeline of candidates. This is an analyst's view of the commercial prospects of their drugs for the treatment of skin and lung cancer.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772513477945 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Checkpoint Therapeutics is a biopharmaceutical company developing cancer treatments based on proven mechanisms of action. Its strategy is aimed at reducing development risks. This chart reflects the overall investment climate, and Checkpoint's progress in clinical trials demonstrates how companies can create value by pursuing more conservative scientific paths.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513477965 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Checkpoint Therapeutics
Checkpoint Therapeutics is a biopharmaceutical company specializing in the development and commercialization of novel cancer treatments. Being in clinical development, it incurs significant research expenses. The chart shows its current financial position, with today's expenses being an investment in potentially life-saving drugs of the future.
Market segment marginality - Cancer cure
Checkpoint Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel cancer treatments, particularly checkpoint inhibitors. This chart reflects its operating expenses during the clinical trial stage. Future profitability depends on the successful approval and commercialization of its products.
Market marginality as a whole
Checkpoint Therapeutics is a biotech company developing immuno-oncology drugs. It is in clinical trials and has no revenue. This total return chart reflects the investment climate. In a favorable economic environment, the company can more easily attract the capital needed to conduct expensive research and bring its drugs to market.
Employees in the company, segment and market as a whole
Number of employees in the company Checkpoint Therapeutics
Checkpoint Therapeutics is a biopharmaceutical company focused on the development and commercialization of targeted therapies and immunotherapies for the treatment of cancer. This chart shows how the company is building its clinical team to conduct pivotal trials and prepare for the commercialization of its oncology portfolio.
Share of the company's employees Checkpoint Therapeutics within the market segment - Cancer cure
Checkpoint Therapeutics is a biotechnology company focused on the development and commercialization of novel cancer treatments. Being in the clinical stage, its staff consists primarily of scientists and clinical trial specialists. This schedule reflects its development model, where investments are primarily directed toward intellectual capital to advance R&D.
Number of employees in the market segment - Cancer cure
Checkpoint Therapeutics is a biopharmaceutical company focused on developing oncology drugs. This chart, which shows employment in the cancer treatment sector, demonstrates the intensity of research and development in this field. For Checkpoint, the growing number of scientists and clinicians indicates intense competition, but also the presence of a well-developed infrastructure for conducting clinical trials.
Number of employees in the market as a whole
Checkpoint Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative cancer treatments. Funding for such companies depends on the overall investment climate. The growth in overall employment shown in this chart indicates a healthy economy, where investors are willing to invest in high-risk but potentially breakthrough biotechnologies.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics (CKPT) is a biotech company working on oncology drugs. This biotech chart is an indicator of concentrated value. Market capitalization is based on expectations for clinical trials and patent value. A small team of scientists can create an asset worth billions, leading to a very high valuation per employee.
%20of%20the%20company%20Checkpoint%20Therapeutics%20(CKPT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Checkpoint-Therapeutics-CKPT&v=1772513478116 "Chart of market capitalization per employee (in thousands of dollars) of the company Checkpoint Therapeutics (CKPT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Checkpoint Therapeutics is a biopharmaceutical company focused on oncology. Its value is determined by its pipeline of potential drugs. This chart demonstrates the high future value the market attributes to its clinical development pipeline, based on its relatively small team of scientists and managers.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772513478118 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Checkpoint Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Its value is almost entirely dependent on the success of clinical trials. This chart for Checkpoint is a prime example of a biotech company where the market value per employee can be colossal, reflecting the hope of developing a new drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513478135 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics is a clinical-stage biotech company focused on oncology drugs. This chart will show a negative value—the investment (loss) per employee. This represents how much the company spends on research and clinical trials.
%20Chart%20Checkpoint%20Therapeutics%20(CKPT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Checkpoint-Therapeutics-CKPT&v=1772513478178 "Company Profit Per Employee (in thousands of dollars) Chart Checkpoint Therapeutics (CKPT)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Checkpoint Therapeutics is a biopharmaceutical company focused on developing innovative cancer treatments. In oncology, where clinical trials are extremely expensive, the effectiveness of the team of scientists and researchers is critical. This chart reflects the value each employee creates, which is essential for assessing the company's potential for commercialization.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772513478191 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Checkpoint Therapeutics is a biotech company focused on developing and commercializing novel cancer treatments (immuno-oncology). This chart, showing the market average revenue per employee, provides important context. It illustrates the high stakes in biotech, where a single successful development can generate colossal revenue per scientist.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513478206 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics is a biopharmaceutical company focused on developing oncology drugs. Being in clinical development, it has no commercial revenue yet. This graph will show zero values, which is typical for R&D companies whose value is determined by the potential of their pipeline of future cancer drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Checkpoint-Therapeutics-CKPT&v=1772513478235 "Sales chart per company employee Checkpoint Therapeutics (CKPT)")
Sales per employee in the market segment - Cancer cure
Checkpoint Therapeutics (CKPT) is a biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutics. This chart shows the average revenue per employee in the sector. It helps investors assess how effectively CKPT utilizes its scientific staff to advance its research compared to other oncology biotechs.
Sales per employee for the market as a whole
Checkpoint Therapeutics (CKPT) is a biotechnology company focused on the development and commercialization of novel cancer treatments (immuno-oncology). The company is in the late clinical stage, preparing to submit applications for approval. This metric, currently near zero, reflects investment in R&D. Investors expect explosive growth if approval and sales begin.
Short shares by company, segment and market as a whole
Shares shorted by company Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics (CKPT) is a clinical-stage oncology company developing biosimilars and novel drugs. This chart shows "short" interest. High values reflect the biotech's enormous risks: investors may doubt the company's ability to obtain FDA approval, fear high cash burn, or fear fierce competition in immuno-oncology. (342)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Checkpoint-Therapeutics-CKPT&v=1772513478288 "Short Shares Chart for the Company Checkpoint Therapeutics (CKPT)")
Shares shorted by market segment - Cancer cure
Checkpoint Therapeutics (CKPT) is a biopharmaceutical company focused on the development and commercialization of new cancer treatments (immuno-oncology). The chart below shows the aggregate short position in the oncology biotech sector. It shows how many investors are skeptical of new developments or fear failure in Phase III.
Shares shorted by the overall market
Checkpoint Therapeutics is a biotech company focused on oncology. It's a classic R&D story. This chart measures the overall level of fear in the market. When it's high, investors are unwilling to fund multi-year clinical trials. They see "yet another unprofitable company" and sell, fearing the "cash" will run out before success.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Checkpoint Therapeutics (CKPT)
Checkpoint Therapeutics (CKPT) is a biotech company developing immuno-oncology drugs, including those for skin cancer. They aim to make treatments more accessible. This oscillator measures momentum. It shows when the stock is "overheated" (above 70) pending an FDA decision or "oversold" (below 30) on news of delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Checkpoint-Therapeutics-CKPT&v=1772513478353 "RSI 14 indicator chart for the company's stock Checkpoint Therapeutics (CKPT)")
RSI 14 Market Segment - Cancer cure
Checkpoint Therapeutics is a biotech company specializing in the development of immuno-oncology drugs (PD-L1 inhibitors) for the treatment of cancer. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated by speculative expectations.
RSI 14 for the overall market
For Checkpoint Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CKPT (Checkpoint Therapeutics)
Checkpoint Therapeutics is a biotech company developing immuno-oncology drugs, including PD-L1 inhibitors. This chart shows the analysts' average 12-month forecast, representing their collective bet that their drugs will receive FDA approval for the treatment of skin cancer.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CKPT-Checkpoint-Therapeutics&v=1772513478415 "A chart showing analyst consensus forecasts for the expected stock price. CKPT (Checkpoint Therapeutics)")
The difference between the consensus estimate and the actual stock price CKPT (Checkpoint Therapeutics)
Checkpoint (CKPT) is an oncology R&D company developing biosimilars and proprietary checkpoint inhibitors (immunotherapies). This chart measures the gap between the current price and the consensus target price. It shows how confident experts are in their ability to bring these drugs to FDA approval.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CKPT-Checkpoint-Therapeutics&v=1772513478422 "A chart showing the difference between the consensus forecast and the actual stock price. CKPT (Checkpoint Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Checkpoint Therapeutics (CKPT) is a biotech company developing biosimilars and new drugs for cancer immunotherapy. This chart shows general expectations for the cancer treatment sector. It reflects whether experts believe R&D will be successful in the hypercompetitive oncology market.
Analysts' consensus forecast for the overall market share price
Checkpoint Therapeutics (CKPT) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market and serves as an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Checkpoint Therapeutics
Checkpoint is a biotech R&D company focused on oncology. Their specialty is the R&D of proprietary (biosimilar?) checkpoint inhibitors (like Keytruda) for the treatment of rare skin cancers. This chart is purely an R&D barometer. It doesn't reflect revenue, but rather a speculative assessment of their (very risky) pipeline and their (difficult) dialogue with the FDA.
AKIMA Market Segment Index - Cancer cure
Checkpoint Therapeutics is an oncology company. They develop checkpoint inhibitors—drugs that release the immune system's brakes, allowing it to attack cancer. This is called immunotherapy. This chart compares their composite index to the sector, showing how their approach to cancer treatment compares to others.
The AKIM Index for the overall market
Checkpoint Therapeutics is an immuno-oncology company developing an antibody (Cosibelimab) for the treatment of skin cancer. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is seeking FDA approval, stacks up against overall economic trends.
